Kevzara
(Sarilumab)ApprovedMonoclonal antibody
Sarilumab is used to treat moderate to severe rheumatoid arthritis, a disease where the immune system attacks joints causing pain and swelling. It can be used alone or with other arthritis medications to reduce symptoms and slow joint damage.[2] Kevzara is currently approved and in use across 9 indications[4].[1]
Kevzara is one of 183 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Approved.
9
Indications
52
Total Trials
13
Active Trials
182
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Lupron
EEastern Cooperative Oncology Group
Phase 3
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Paraplatin
AAvyxa
Phase 3
Tecentriq
RochePhase 3
Nizoral
WWim Janssens
Phase 3
Ritalin
NovartisPhase 3
Semaglutide Pen Injector
UUniversitaire Ziekenhuizen KU Leuven
Phase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis14 trials
Show 11 more trials
COVID-199 trials
Show 6 more trials
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Unknown status·—·Phase 2·NCT04661527·60 enrolled
Polymyalgia Rheumatica2 trials
ESS2 trials
22 more indications
Ovarian Cancer2 trials
Systemic Juvenile Idiopathic Arthritis1 trial
Biologics1 trial
Melanoma1 trial
Drug1 trial
Breast Cancer1 trial
Tocilizumab1 trial
Prostate Cancer1 trial
Systemic Mastocytosis1 trial
Contact Dermatitis1 trial
Pneumonia1 trial
Juvenile Idiopathic Arthritis1 trial
Methotrexate1 trial
Hospitalized Patients1 trial
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19
Withdrawn·—·Phase 2·NCT07196306
Recurrent Ovarian Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Regulatory
FDA Approval Timeline[5]
May 22, 2017
KEVZARA
BLA BLA761037
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Kevzara drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sarilumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details